...
首页> 外文期刊>Biochimica et biophysica acta. Biomembranes >Thrombocidin-1-derived antimicrobial peptide TC19 combats superficial multi-drug resistant bacterial wound infections
【24h】

Thrombocidin-1-derived antimicrobial peptide TC19 combats superficial multi-drug resistant bacterial wound infections

机译:血小菌蛋白-1-衍生的抗微生物肽TC19作用浅表多药物耐药细菌感染

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Antimicrobial peptides are considered promising candidates for the development of novel antimicrobial agents to combat infections by multi-drug-resistant (MDR) bacteria. Here, we describe the identification and characterization of the synthetic peptide TC19, derived from the human thrombocidin-l-derived peptide L3. Biophysical experiments into the interaction between TC19 and mimics of human and bacterial plasma membranes demonstrated that the peptide is highly selective for bacterial membranes. In agreement, TC19 combined low cytotoxicity towards human fibroblasts with efficient and rapid killing in human plasma of MDR strains of several bacterial species of the ESKAPE panel. In addition, TC19 induced minor resistance in vitro, neutralized pro-inflammatory activity of bacterial cell envelope components while displaying slight chemotactic activity for human neutrophils. Importantly, topical application of TC19-containing hypromellose gel significantly reduced numbers of viable methicillin-resistant Staphylococcus aureus (MRSA) and MDR Acinetobacter baumannii in a superficial wound infection in mice. Together, TC19 is an attractive candidate for further development as a novel agent against (MDR) bacterial skin wound infections.
机译:抗微生物肽被认为是开发新型抗微生物剂以应对多种耐药性(MDR)细菌的感染的有前途的候选者。在此,我们描述了来自人血小丙酯-1衍生的肽L3的合成肽TC19的鉴定和表征。生物物理实验进入TC19与人和细菌血浆膜模拟物之间的相互作用证明肽对细菌膜具有高度选择性。在协议中,TC19将低细胞毒性与人成纤维细胞的低细胞毒性与ESKape小组的几种细菌种类的MDR菌株的人体血浆有效且快速杀死。此外,TC19在体外诱导细菌细胞包络组分的中和促炎活性,同时为人性粒细胞显示轻微的趋化活性。重要的是,含TC19的含杂蛋白凝胶的局部施用显着减少了在小鼠的浅表伤口感染中的活性甲氧化酰硫脲葡萄球菌(MRSA)和MDR acinetobacterBaumannii的数量。 TC19在一起是一种有吸引力的候选者,用于进一步发展作为一种针对(MDR)细菌皮肤伤口感染的新型药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号